Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Jesús San-Miguel, Joan Bladé, Ofer Shpilberg, Sebastian Grosicki, Frédéric Maloisel, Chang Ki Min, Marta Polo Zarzuela, Tadeusz Robak, Sripada V.S.S. Prasad, Yeow Tee Goh, Jacob Laubach, Andrew Spencer, María Victoria Mateos, Antonio Palumbo, Tom Puchalski, Manjula Reddy, Clarissa Uhlar, Xiang Qin, Helgi Van De Velde, Hong XieRobert Z. Orlowski
Research output: Contribution to journal › Article › peer-review
123Scopus
citations
Fingerprint
Dive into the research topics of 'Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma'. Together they form a unique fingerprint.